Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer

Molecular Oncology

Volumn 6, Issue 1, 2012, Pages 15-26

  Dienstmann, Rodrigo ^a   De Dosso, Sara ^b   Felip, Enriqueta ^a   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

Biomarker; Epidermal growth factor receptor; Monoclonal antibody; Resistance; Tyrosine kinase inhibitor

Indexed keywords

AFATINIB; BEVACIZUMAB; BIOLOGICAL MARKER; BMS 690514; BRIVANIB; CABOZANTINIB; CETUXIMAB; CIXUTUMUMAB; DACOMITINIB; DALOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FIGITUMUMAB; GANITUMAB; GDC 0973; GEFITINIB; K RAS PROTEIN; MK 2206; MONOCLONAL ANTIBODY; NERATINIB; ONARTUZUMAB; PANITUMUMAB; PICTRELISIB; PROTEIN TYROSINE KINASE INHIBITOR; RILOTUMUMAB; SELUMETINIB; SOMATOMEDIN C RECEPTOR; SUNITINIB; TIVANTINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ADD ON THERAPY; CANCER RESISTANCE; COLORECTAL CANCER; DRUG TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; VALIDATION STUDY; WILD TYPE;

EID: 84856266000     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2011.11.009     Document Type: Review

References (83)

1. Arcila M.E., Oxnard G.R., Nafa K., Riely G.J., Solomon S.B., Zakowski M.F., Kris M.G., Pao W., Miller V.A., Ladanyi M. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin. Cancer Res. 2011, 17:1169-1180.
2. Bahleda R., Soria J.C., Harbison C.T., Park J., Felip E., Hanna N., Laurie S.A., Armand J., Shepherd F.A., Herbst R. Tumor regression and pharmacodynamic biomarker validation in non-small cell lung cancer patients treated with the ErbB/VEGFR inhibitor BMS-690514. J. Clin. Oncol. 2009, 27. abstract 431s.
3. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9:463-475.
4. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., Chitale D., Motoi N., Szoke J., Broderick S., Balak M., Chang W.C., Yu C.J., Gazdar A., Pass H., Rusch V., Gerald W., Huang S.F., Yang P.C., Miller V., Ladanyi M., Yang C.H., Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:20932-20937.
5. Campbell A., Reckamp K.L., Camidge D.R., Giaccone G., Gadgeel S.M., Khuri F.R., Engelman J.A., Denis L.J., O'Connell J.P., Jänne P.A. PF-00299804 (PF299) patient reported outcomes and efficacy in adenocarcinoma and non-adeno non-small cell lung cancer: a phase II trial in advanced NSCLC after failure of chemotherapy and erlotinib. J. Clin. Oncol. 2010, 28. abstract 7596.
6. Campoli M., Ferris R., Ferrone S., Wang X. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin. Cancer Res. 2010, 16:11-20.
7. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., Haney J., Witta S., Danenberg K., Domenichini I., Ludovini V., Magrini E., Gregorc V., Doglioni C., Sidoni A., Tonato M., Franklin W.A., Crino L., Bunn P.A., Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 2005, 97:643-655.
8. Cappuzzo F., Varella-Garcia M., Finocchiaro G., Skokan M., Gajapathy S., Carnaghi C., Rimassa L., Rossi E., Ligorio C., Di Tommaso L., Holmes A.J., Toschi L., Tallini G., Destro A., Roncalli M., Santoro A., Jänne P.A. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br. J. Cancer 2008, 99:83-89.
9. Cohen R.B., Jänne P.A., Engelman J.A., Martínez P., Nishida Y., Gendreau S., Wu B., Felip E. A phase I safety and pharmacokinetic study of PI3K/TORC1/ TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib in patients with advanced solid tumors. J. Clin. Oncol. 2010, 28. abstract 3015.
10. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., Kalogeras K.T., Kotoula V., Papamichael D., Laurent-Puig P., Penault-Llorca F., Rougier P., Vincenzi B., Santini D., Tonini G., Cappuzzo F., Frattini M., Molinari F., Saletti P., De Dosso S., Martini M., Bardelli A., Siena S., Sartore-Bianchi A., Tabernero J., Macarulla T., Di Fiore F., Gangloff A.O., Ciardiello F., Pfeiffer P., Qvortrup C., Hansen T.P., Van Cutsem E., Piessevaux H., Lambrechts D., Delorenzi M., Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011, 12:594-603.
11. Di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S., Bardelli A. BRAF wild-type is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:5705-5712.
12. Dienstmann R., Tolcher A.W., Papadopoulos K.P., Rasco D.W., Tabernero J., Brana I., Piera A., Skartved N.J., Aladdin H., Petersen J., Patnaik A. Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors. J. Clin. Oncol. 2011, 29. abstract 3089.
13. Dienstmann R., Vilar E., Tabernero J. Molecular predictors of response to chemotherapy in colorectal cancer. Cancer J. 2011, 17:114-126.
14. Eng C., Van Cutsem E., Nowara E., Swieboda-Sadlej A., Tebbutt N.C., Mitchell E.P., Davidenko I., Oliner K., Chen L., Huang J., McCaffery I., Loh E., Smethurst D., Tabernero J. A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients with wild-type KRAS metastatic colorectal cancer. J. Clin. Oncol. 2011, 29. abstract 3500.
15. Engelman J.A., Zejnullahu K., Gale C.M., Lifshits E., Gonzales A.J., Shimamura T., Zhao F., Vincent P.W., Naumov G.N., Bradner J.E., Althaus I.W., Gandhi L., Shapiro G.I., Nelson J.M., Heymach J.V., Meyerson M., Wong K.K., Jänne P.A. PF00299804, an irreversible pan- ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007, 67:11924-11932.
16. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Jänne P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
17. Felip E., Salcedo M., Murtra-Garrell N., Navarro A., Teixido C., Hernandez-Losa J., Cedres S., Martinez P., Lopez E., Montero M.A., Freixinos V., Argiles G., Nuñez I., Peg V., Pallisa E., Canela M., Tabernero J., Ramon y Cajal S., Tallada N. Expression of ErbB2 and ErbB3 in resected non-small cell lung cancer patients. J. Clin. Oncol. 2011, 29. abstract 7037.
18. Gerdes C., Patre M., Nicolini V., Moessner E., Klingner G., Bruenker P., Moser S., Grau R., Schmidt C., Guarino B., Sondermann P., Jaegar C., Preiss S., van Puijenbroek E., Bossenmaier B., Ries C., Friess T., Umana P. GA201, a novel humanized, glycoengineered EGFR antibody with enhanced ADCC and superior invivo efficacy in xenograft models. Proc. Am. Assoc. Cancer Res. 2008, abstract 3973.
19. Guix M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., Rinehart C., Seidel B., Yee D., Arteaga C.L., Engelman J.A. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 2008, 18:2609-2619.
20. Hecht J.R., Mitchell E., Chidiac T., Scroggin C., Hagenstad C., Spigel D., Marshall J., Cohn A., McCollum D., Stella P., Deeter R., Shahin S., Amado R.G. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 2009, 27:672-680.
21. Herbst R.S., Ansari R., Bustin F., Flynn P., Hart L., Otterson G.A., Vlahovic G., Soh C.H., O'Connor P., Hainsworth J. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011, 377:1846-1854.
22. Hu Y.P., Patil S.B., Panasiewicz M., Li W., Hauser J., Humphrey L.E., Brattain M.G. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. Cancer Res. 2008, 68:8004-8013.
23. Inukai M., Toyooka S., Ito S., Asano H., Ichihara S., Soh J., Suehisa H., Ouchida M., Aoe K., Aoe M., Kiura K., Shimizu N., Date H. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 2006, 66:7854-7858.
24. Jackman D., Pao W., Riely G.J., Engelman J.A., Kris M.G., Jänne P.A., Lynch T., Johnson B.E., Miller V.A. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:357-360.
25. Janjigian Y.Y., Azzoli C.G., Krug L.M., Pereira L.K., Rizvi N.A., Pietanza M.C., Kris M.G., Ginsberg M.S., Pao W., Miller V.A., Riely G.J. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin. Cancer Res. 2011, 17:2521-2527.
26. Janjigian Y.Y., Groen H.J., Horn L., Smit E.F., Fu Y., Wang F., Shahidi M., Denis L.J., Pao W., Miller V.A. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J. Clin. Oncol. 2011, 29. abstract 7525^.
27. Kammula U.S., Kuntz E.J., Francone T.D., Zeng Z., Shia J., Landmann R.G., Paty P.B., Weiser M.R. Molecular coexpressionof the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 2007, 248:219-228.
28. Khambata-Ford S., Harbison C.T., Hart L.L., Awad M., Xu L.A., Horak C.E., Dakhil S., Hermann R.C., Lynch T.J., Weber M.R. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:918-927.
29. Kopetz S., Desai J., Chan E., Hecht J.R., O'Dwyer P.J., Lee R.J., Nolop K.B., Saltz L. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Oncol. 2010, 28. abstract 3534.
30. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., Tada H., Kuwano H., Mitsudomi T. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res. 2006, 12:5764-5769.
31. Kurzrock R., Patnaik A., Rosenstein A., Fu S., Papadopoulos K.P., Smith D.A., Falchook G.S., Chambers G., Gauvin J.L., Naing A., Smith L.S., Gonzalez T., Tsimberidou A.M., Mays T.A., Cox D.S., Hong D.S., DeMarini D.J., Le N.T., Morris S.R., Tolcher A.W. Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). J. Clin. Oncol. 2011, 29. abstract 3085.
32. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., Harris P.L., Driscoll D.R., Fidias P., Lynch T.J., Rabindran S.K., McGinnis J.P., Wissner A., Sharma S.V., Isselbacher K.J., Settleman J., Haber D.A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:7665-7670.
33. Lee J.C., Wang S.T., Chow N.H., Yang H.B. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur. J. Cancer 2002, 38:1065-1071.
34. Leighl N.B., Soria J.C., Bennouna J., Blais N., Traynor A.M., Papadimitrakopoulou V., Klimovsky J., Jappe A., Jehl V., Johnson B.E. Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer. J. Clin. Oncol. 2010, 28. abstract 7524.
35. Li D., Ambrogio L., Shimamura T., Kubo S., Takahashi M., Chirieac L.R., Padera R.F., Shapiro G.I., Baum A., Himmelsbach F., Rettig W.J., Meyerson M., Solca F., Greulich H., Wong K.K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711.
36. Liévre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., Côté J.F., Tomasic G., Penna C., Ducreux M., Rougier P., Penault-Llorca F., Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66:3992-3995.
37. Lynch T.J., Bell D.W., Sordell R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
38. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., Gemma A., Harada M., Yoshizawa H., Kinoshita I., Fujita Y., Okinaga S., Hirano H., Yoshimori K., Harada T., Ogura T., Ando M., Miyazawa H., Tanaka T., Saijo Y., Hagiwara K., Nukiwa T., North-East Japan Study Group Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010, 362:2380-2388.
39. Miller V.A., Hirsh V., Cadranel J., Chen Y.-M., Park K., Kim S.W., Caicun Z., Oberdick M., Shahidi M., Yang C.H. Phase IIB/ III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of the EGFR/HER1 and HER2) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-LUNG 1). Ann. Oncol. 2010, 21:viii122-viii161. abstract LBA1.
40. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., Seto T., Satouchi M., Tada H., Hirashima T., Asami K., Katakami N., Takada M., Yoshioka H., Shibata K., Kudoh S., Shimizu E., Saito H., Toyooka S., Nakagawa K., Fukuoka M., West Japan Oncology Group Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010, 11:121-128.
41. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., Nishiwaki Y., Ohe Y., Yang J.J., Chewaskulyong B., Jiang H., Duffield E.L., Watkins C.L., Armour A.A., Fukuoka M. Gefitinib or paclitaxel-carboplatin in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361:947-957.
42. Mok T., Spigel D.R., Park K., Socinski M.A., Tung S.Y., Kim D.-W., Ou S.-H.I., Zhang H., O'Connell J.P., Jänne P. Efficacy and safety of PF299804 as first-line treatment of patients with advanced NSCLC selected for activating mutation of epidermal growth factor receptor (EGFR). Ann. Oncol. 2010, 21:viii122-viii161. abstract LBA18.
43. Morgillo F., Woo J.K., Kim E.S., Hong W.K., Lee H.Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 2006, 66:10100-10111.
44. Natale R.B., Thongprasert S., Greco F.A., Thomas M., Tsai C.M., Sunpaweravong P., Ferry D., Mulatero C., Whorf R., Thompson J., Barlesi F., Langmuir P., Gogov S., Rowbottom J.A., Goss G.D. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). J. Clin. Oncol. 2009, 27. abstract 409s.
45. O'Byrne K.J., Bondarenko I., Barrios C., Eschbach C., Martens U., Hotko Y., Kortsik C., Celik I., Stroh C., Pirker R. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the FLEX study. J. Clin. Oncol. 2009, 27. abstract 8007.
46. Ouban A., Muraca P., Yeatman T., Coppola D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum. Pathol. 2003, 34:803-808.
47. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., Zakowski M.F., Heelan R.T., Kris M.G., Varmus H.E. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005, 2:e17.
48. Paz-Ares L.G., Gomez-Roca C., Delord J.P., Cervantes A., Markman B., Corral J., Soria J.C., Bergé Y., Roda D., Russell-Yarde F., Hollingsworth S., Baselga J., Umana P., Manenti L., Tabernero J. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. 2011, 29:3783-3790.
49. Pedersen M.W., Jacobsen H.J., Koefoed K., Hey A., Pyke C., Haurum J.S., Kragh M. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res. 2010, 70:588-597.
50. Regales L., Gong Y., Shen R., de Stanchina E., Vivanco I., Goel A., Koutcher J.A., Spassova M., Ouerfelli O., Mellinghoff I.K., Zakowski M.F., Politi K.A., Pao W. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J. Clin. Invest. 2009, 119:3000-3010.
51. Reidy D.L., Vakiani E., Fakih M.G., Saif M.W., Hecht J.R., Goodman-Davis N., Hollywood E., Shia J., Schwartz J., Chandrawansa K., Dontabhaktuni A., Youssoufian H., Solit D.B., Saltz L.B. Randomized, phase II study of the Insulin-Like Growth Factor-1 Receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J. Clin. Oncol. 2010, 28:4240-4246.
52. Rosell R., Gervais R., Vergnenegre A., Massuti B., Felip E., Cardenal F., Garcia Gomez R., Pallares R., Sanchez J.M., Porta R., Cobo M., Di Seri M., Garrido Lopez P., Insa A., De Marinis F., Corre R., Carreras M., Carcereny E., Taron M., Paz-Ares L.G. Erlotinib versus chemotherapy in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J. Clin. Oncol. 2011, 29. abstract 7503.
53. Rosell R., Molina M.A., Costa C., Simonetti S., Gimenez-Capitan A., Bertran-Alamillo J., Mayo C., Moran T., Mendez P., Cardenal F., Isla D., Provencio M., Cobo M., Insa A., Garcia-Campelo R., Reguart N., Majem M., Viteri S., Carcereny E., Porta R., Massuti B., Queralt C., de Aguirre I., Sanchez J.M., Sanchez-Ronco M., Mate J.L., Ariza A., Benlloch S., Sanchez J.J., Bivona T.G., Sawyers C.L., Taron M. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin. Cancer Res. 2011, 17:1160-1168.
54. Rosell, R., Moran, T., Felip, E., Sanchez Torres, J., Borghaei, H., Guan, S., Brown, H., Fitzgerald, T., Clark, J., Sathyanarayanan, S., Ayers, M., Hardwick, J., Lu, B., Yan, L., Johnson, D., 2011c. An open label, randomized Ph II study evaluating dalotuzumab combined with erlotinib in patients with non-small cell lung cancer following failure of prior chemotherapy. 14th World Conference on Lung Cancer, abstract O19.02.
55. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995, 19:183-232.
56. Saltz L.B., Lenz H.J., Kindler H.L., Hochster H.S., Wadler S., Hoff P.M., Kemeny N.E., Hollywood E.M., Gonen M., Quinones M., Morse M., Chen H.X. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol. 2007, 25:4557-4561.
57. Scagliotti G.V., Krzakowski M., Szczesn A., Strausz J., Makhson A., Reck M., Tye L., Selaru P., Chao R.C., Govindan R. Sunitinib in combination with erlotinib for the treatment of advanced/metastatic non-small cell lung cancer: a phase III study. Ann. Oncol. 2010, 21:viii3. abstract LBA6.
58. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 2006, 12:5268-5272.
59. Scartozzi M., Mandolesi A., Giampieri R., Pierantoni C., Loupakis F., Zaniboni A., Galizia E., Giustini L., Silva R.R., Bisonni R., Berardi R., Biagetti S., Menzo S., Falcone A., Bearzi I., Cascinu S. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int. J. Cancer 2010, 127:1941-1947.
60. Scartozzi M., Mandolesi A., Giampieri R., Bittoni A., Pierantoni C., Zaniboni A., Galizia E., Giustini L., Silva R.R., Bisonni R., Berardi R., Biscotti T., Biagetti S., Bearzi I., Cascinu S. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan/cetuximab. Oncologist 2011, 16:53-60.
61. Schaefer G., Haber L., Crocker L.M., Shia S., Shao L., Dowbenko D., Totpal K., Wong A., Lee C.V., Stawicki S., Clark R., Fields C., Lewis Phillips G.D., Prell R.A., Danilenko D.M., Franke Y., Stephan J.P., Hwang J., Wu Y., Bostrom J., Sliwkowski M.X., Fuh G., Eigenbrot C. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011, 20:472-486.
62. Seiden-Long I.M., Brown K.R., Shihn W., Wigle D.A., Radulovich N., Jurisica I., Tsao M.S. Transcriptional targets of hepatocyte growth factor signaling and K-ras oncogene activation in colorectal cancer. Oncogene 2006, 25:91-102.
63. Sequist L.V., Besse B., Lynch T.J., Miller V.A., Wong K.K., Gitlitz B., Eaton K., Zacharchuk C., Freyman A., Powell C., Ananthakrishnan R., Quinn S., Soria J.C. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:3076-3083.
64. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., Bergethon K., Shaw A.T., Gettinger S., Cosper A.K., Akhavanfard S., Heist R.S., Temel J., Christensen J.G., Wain J.C., Lynch T.J., Vernovsky K., Mark E.J., Lanuti M., Iafrate A.J., Mino-Kenudson M., Engelman J.A. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011, 3. 75ra26.
65. Sequist L.V., von Pawel J., Garmey E.G., Akerley W.L., Brugger W., Ferrari D., Chen Y., Costa D.B., Gerber D.E., Orlov S., Ramlau R., Arthur S., Gorbachevsky I., Schwartz B., Schiller J.H. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J. Clin. Oncol. 2011, 29:3307-3315.
66. Shapiro G., LoRusso P., Kwak E.L., Cleary J.M., Musib L., Jones C., de Crespigny A., Belvin M., McKenzie M., Gates M.R., Chan I.T., Bendell J.C. Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: a first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. J. Clin. Oncol. 2011, 29. abstract 3005^.
67. Shapiro J.D., Siu L.L., Zalcberg J.R., Moore M.J., Ringash J., Mittmann N., Simes J., O'Callaghan C.J., Tu D., Walters I.B., Magoski N., Smith P., Nomikos D., Zhu L., Savoie M., Virk S., El-Tahche F., Gill R., Price T.J., Jonker D.J. A phase III study of cetuximab plus either brivanib alaninate versus placebo in patients with chemotherapy-refractory KRAS wild-type advanced colorectal cancer: the NCIC CTG/AGITG CO.20 trial. J. Clin. Oncol. 2011, 29. abstract TPS163.
68. Shih J., Yu C., Su W., Hsia T., Graziano S.L., Calvo R., Cong X.J., Shahidi M., Yang C., Miller V. Activity of BIBW 2992, an irreversible EGFR/HER1 and HER2 TKI, in lung adenocarcinoma patients harbouring less common EGFR mutations. Ann. Oncol. 2010, 21:viii122-viii161. abstract 415P.
69. Spigel D.R., Burris H.A., Greco F.A., Shipley D.L., Friedman E.K., Waterhouse D.M., Whorf R.C., Mitchell R.B., Daniel D.B., Zangmeister J., Bass J.D., Hainsworth J.D. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 2011, 29:2582-2589.
70. Spigel D.R., Ervin T.J., Ramlau R., Daniel D.B., Goldschmidt J.H., Blumenschein G.R., Krzakowski M.J., Robinet G., Clement-Duchene C., Barlesi F., Govindan R., Patel T., Orlov S.V., Wertheim M.S., Zha J., Pandita A., Yu W., Yauch R.L., Patel P.H., Peterson A.C. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J. Clin. Oncol. 2011, 29. abstract 7505.
71. Tabernero, J., Garcia-Carbonero, R., Köhne, C.H., O'Dwyer, P.J., Sobrero, A., Van Cutsem, E., Gladkov, O., Davidenko, I., Salazar, R., Cassidy, J., 2011. A phase 2b, double-blind, randomized study evaluating the efficacy and safety of sorafenib compared with placebo when administered in combination with chemotherapy (modified FOLFOX6) for first-line treatment of patients with metastatic colorectal cancer (mCRC): the RESPECT trial. ESMO/ ECCO Conference Stockholm, abstract LBA19.
72. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., Erdkamp F.L., Vos A.H., van Groeningen C.J., Sinnige H.A., Richel D.J., Voest E.E., Dijkstra J.R., Vink-Börger M.E., Antonini N.F., Mol L., van Krieken J.H., Dalesio O., Punt C.J. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 2009, 360:563-572.
73. Tolcher A.W., Baird R.D., Patnaik A., Moreno Garcia V., Papadopoulos K.P., Garrett C.R., Olmos D., Shannon K.A., Zazulina V., Rubin E.H., Smith I.C., Ryan J., Smith P.D., Taylor A., Learoyd M., Lupinacci L., Yan L., De Bono J.S. A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. J. Clin. Oncol. 2011, 29. abstract 3004.
74. Turke A.B., Zejnullahu K., Wu Y.L., Song Y., Dias-Santagata D., Lifshits E., Toschi L., Rogers A., Mok T., Sequist L., Lindeman N.I., Murphy C., Akhavanfard S., Yeap B.Y., Xiao Y., Capelletti M., Iafrate A.J., Lee C., Christensen J.G., Engelman J.A., Jänne P.A. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
75. Viloria-Petit A., Crombet T., Jothy S., Hicklin D., Bohlen P., Schlaeppi J.M., Rak J., Kerbel R.S. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies invivo: a role for altered tumor angiogenesis. Cancer Res. 2001, 61:5090-5101.
76. Wakelee H.A., Gettinger S.N., Engelman J.A., Jänne P.A., West H.J., Subramaniam D.S., Leach J.W., Wax M.B., Yaron Y., Lara P. A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib in patients with non-small cell lung cancer. J. Clin. Oncol. 2010, 28. abstract 3017.
77. Watkins D.J., Tabernero J., Schmoll H., Trarbach T., Ramos F.J., Howe J., Brown H.M., Clark J., Hsu K., Lu B.D., Cunningham D. A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab and irinotecan in the treatment of chemorefractory metastatic colorectal cancer with wild-type KRAS status. J. Clin. Oncol. 2011, 29. abstract 3501.
78. Weber M.M., Fottner C., Liu S.B., Jung M.C., Engelhardt D., Baretton G.B. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 2002, 95:2086-2095.
79. Wee S., Jagani Z., Xiang K.X., Loo A., Dorsch M., Yao Y.M., Sellers W.R., Lengauer C., Stegmeier F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 2009, 69:4286-4293.
80. Weinstein I.B. Addiction to oncogenes - the achilles heal of cancer. Science 2002, 297:63-64.
81. Yang C., Shih J., Su W., Hsia T., Sequist L.V., Chang G., Calvo R., Cong X.J., Shahidi M., Miller V. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-LUNG 2). Ann. Oncol. 2010, 21:viii122-viii161. abstract 367PD.
82. Yonesaka K., Okamoto I., Satoh T., Takeda K., Takada M., Nishio K., Fukuoka M., Saijo N., Jänne P.A., Nakagawa K. Heregulin as a novel cetuximab-resistance factor in colorectal cancer. J. Clin. Oncol. 2010, 28. abstract e14044.
83. Zhou C., Wu Y.-L., Chen G., Feng J., Liu X., Wang C., Zhang S., Wang J., Zhou S., Ren S. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine, in Chinese advanced non-small-cell lung cancer patients with EGFR activating mutations. Ann. Oncol. 2010, 21:viii122-viii161. abstract LBA13.